Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Fig. 3

T-cell activation and cytotoxic function in TILs from TNBC-bearing hu-CB-BRGS mice treated with nivolumab. a, Quantification of human T-cells (hCD45 + CD3+) that were stained for expression of activation-marker HLA-DR (left) or CD3 (right). b, Representative flow cytometric analyses showing gating strategy for identification of GrB and IFNγ secreting T-cells. Frequency of GrB+ (left), Tbet+IFNg+ (middle) and number of IFNγ+ (right) among human T-cells. c, Representative flow cytometric analyses (left) showing gating strategy for identification of Treg (FoxP3+) cells and data from each tissue is shown in graphs (right). d, Representative flow cytometric analyses showing gating strategy to measure expression levels of human PD-1 and Tim3 inhibitory receptors on T-cells from hu-CB-BRGS mice. The MFI expression of PD-1 and Tim3 is determined for both CD4 and CD8 T-cell subsets and graphed in top (PD-1) and bottom (Tim3) panels. Each dot represents data from the indicated organ from an individual hu-CB-BRGS mouse that was either untreated (−, black) or treated with nivolumab (+, blue) for 11 or 21 days, as indicated. P-values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001

Back to article page